Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

NCT02155465 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Ruxolitinib
DRUG: Erlotinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]